Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7636300 | 0.88 | NPC1 (0.35) | NPC1ALDH1A1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL7633102 | 0.88 | ADORA3 (0.36) | ALDH1A1HTTMAPK8 | |
| SCHEMBL7636319 | 0.87 | MEN1 (0.38) | NPC1ALDH1A1MAPK1RAB9AMAPK8 | |
| SCHEMBL7633778 | 0.86 | PGK1 (0.36) | NPC1ALDH1A1RAB9AHTT | |
| SCHEMBL7634469 | 0.86 | NPC1 (0.37) | NPC1ALDH1A1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL7640054 | 0.86 | TLR8 (0.38) | NPC1ALDH1A1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL7124810 | 0.85 | TLR8 (0.34) | NPC1ALDH1A1MAPK1RAB9AHTT | |
| SCHEMBL7126094 | 0.84 | MAPT (0.35) | NPC1ALDH1A1MAPK1RAB9AHTT | |
| SCHEMBL7123826 | 0.84 | MAPT (0.35) | NPC1ALDH1A1MAPK1RAB9AHTT | |
| SCHEMBL7125685 | 0.84 | MAPT (0.35) | NPC1ALDH1A1MAPK1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455054-B2 | THERAPY FOR SKIN DISORDERS | SOCIETE L'OREAL S.A. (FR) | 2002-09-24 | — | — | US | claimed |
| US-20010051139-A1 | TREATING SKIN AFFLICTIONS/CONDITIONS WITH 2-AMINO-4-ALKYLAMINOPYRIMIDINE 3-OXIDE COMPOUNDS | SOCIETE L'OREAL S.A. (FR) | 2001-12-13 | — | — | US | claimed |
| US-6455054-B2 | THERAPY FOR SKIN DISORDERS | SOCIETE L'OREAL S.A. (FR) | 2002-09-24 | — | — | US | disclosed |
| US-20010051139-A1 | TREATING SKIN AFFLICTIONS/CONDITIONS WITH 2-AMINO-4-ALKYLAMINOPYRIMIDINE 3-OXIDE COMPOUNDS | SOCIETE L'OREAL S.A. (FR) | 2001-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051139-A1 | TREATING SKIN AFFLICTIONS/CONDITIONS WITH 2-AMINO-4-ALKYLAMINOPYRIMIDINE 3-OXIDE COMPOUNDS | TPMT, IL33, PTGS2 | NPC1 4644/4885ALDH1A1 1072/4885MAPK1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.